SynDevRx, Inc.
Boston
Massachusetts
United States
7 articles about SynDevRx, Inc.
-
Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones
3/28/2024
SynDevRx, Inc., a pioneering clinical-stage biotechnology company based in Cambridge, Massachusetts, has achieved a significant milestone.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance
6/1/2022
SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320).
-
SynDevRx To Present Pre-Clinical Combination Data of Evexomostat (SDX-7320) with Capivasertib (AZD-5363) During The 2021 San Antonio Breast Cancer Symposium
12/8/2021
SynDevRx, Inc. today announced they will be presenting pre-clinical mechanistic/molecular data with evexomostat (SDX-7320) using the Her2+ xenograft model (BT474) in combination with capivasertib/AZD-5363 during the 2021 San Antonio Breast Cancer Symposium.
-
SynDevRx Announces Research Collaboration with Queensland University of Technology (QUT) to Study the Effects of SDX-7320 In Advanced Prostate Cancer Models
12/7/2021
SynDevRx, Inc. today announced a research collaboration with Australia’s Queensland University of Technology.
-
Biotech, science, medical coalition launches Metabo-oncology.com to help solve deadly cancer-obesity crisis
3/26/2019
In recent years, evidence has increasingly shown links between cancer and obesity.
-
New Biotech SynDevRx, Inc. Establishes Scientific Advisory Board with Key Anti-Angiogenesis and Oncology Leaders
1/8/2008